Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Natasha on +44 1494 818 053 or natasha@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Natasha Wilson
Executive Recruiter
natasha@zenopa.com
+44 1494 818 053

Testimonials
Zenopa has helped me find my next role and it was a pleasure to work with them. They were available at all times by phone or email and always ensured I was prepared for interviews.
Emma, 2014

Novartis licenses wet AMD drug from Ophthotech

21 May 2014 11:04 in Pharmaceutical Company Product News


Novartis licenses wet AMD drug from OphthotechNovartis has signed a licensing and commercialisation agreement with Ophthotech for a new treatment for wet age-related macular degeneration (wet AMD).

The deal gives Novartis the right to market the drug Fovista in territories outside the US, in exchange for an upfront fee of $200 million (118.38 million pounds) and potential future recruitment and other milestone payments, plus sales-based royalties.

Fovista is currently being studied in combination with anti-VEGF agents as a treatment for wet AMD. Novartis is also set to develop a new co-formulation of Fovista with one of its own proprietary anti-VEGF treatments.

In phase II clinical studies, a combination therapy of Fovista and Lucentis was shown to significantly improve baseline visual acuity in wet AMD patients

David Epstein, division head at Novartis Pharmaceuticals, said: "If approved, Fovista is expected to be the first to market in this class of therapies for wet AMD, confirming our commitment and leadership in the ophthalmology space."

Last month, the company announced positive phase IV trial data for Onbrez Breezhaler, showing the approved product's effectiveness in treating chronic obstructive pulmonary disease.ADNFCR-8000103-ID-801721954-ADNFCR

Other news stories from 21/05/2014

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2015 Zenopa Ltd